266 related articles for article (PubMed ID: 19070633)
1. Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice.
Byler SL; Boehm GW; Karp JD; Kohman RA; Tarr AJ; Schallert T; Barth TM
Behav Brain Res; 2009 Mar; 198(2):434-9. PubMed ID: 19070633
[TBL] [Abstract][Full Text] [Related]
2. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
3. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
4. Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.
Kim ST; Son HJ; Choi JH; Ji IJ; Hwang O
Brain Res; 2010 Jan; 1306():176-83. PubMed ID: 19804765
[TBL] [Abstract][Full Text] [Related]
5. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
6. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
[TBL] [Abstract][Full Text] [Related]
7. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
[TBL] [Abstract][Full Text] [Related]
8. Ethylenebisdithiocarbamate enhances MPTP-induced striatal dopamine depletion in mice.
McGrew DM; Irwin I; Langston JW
Neurotoxicology; 2000 Jun; 21(3):309-12. PubMed ID: 10894120
[TBL] [Abstract][Full Text] [Related]
9. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum.
Chan P; Langston JW; Di Monte DA
J Pharmacol Exp Ther; 1993 Dec; 267(3):1515-20. PubMed ID: 8263813
[TBL] [Abstract][Full Text] [Related]
10. Systemic proteasomal inhibitor exposure enhances dopamine turnover and decreases dopamine levels but does not affect MPTP-induced striatal dopamine depletion in mice.
Hirst SJ; Ferger B
Synapse; 2008 Feb; 62(2):85-90. PubMed ID: 17992685
[TBL] [Abstract][Full Text] [Related]
11. H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice.
Koga K; Mori A; Ohashi S; Kurihara N; Kitagawa H; Ishikawa M; Mitsumoto Y; Nakai M
Eur J Neurosci; 2006 Feb; 23(4):1077-81. PubMed ID: 16519673
[TBL] [Abstract][Full Text] [Related]
12. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Holmer HK; Keyghobadi M; Moore C; Meshul CK
Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
[TBL] [Abstract][Full Text] [Related]
13. Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Joniec I; Ciesielska A; Kurkowska-Jastrzebska I; Przybylkowski A; Czlonkowska A; Czlonkowski A
Brain Res; 2009 Mar; 1261():7-19. PubMed ID: 19401171
[TBL] [Abstract][Full Text] [Related]
14. [The effect of prolyl-leucyl-glycine (MIF-1) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine levels of the striatum].
Sheng JG
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Aug; 22(4):213-5, 253. PubMed ID: 2575971
[TBL] [Abstract][Full Text] [Related]
15. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
[TBL] [Abstract][Full Text] [Related]
16. Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.
Knaryan VH; Samantaray S; Varghese M; Srinivasan A; Galoyan AA; Mohanakumar KP
Neuropeptides; 2006 Aug; 40(4):291-8. PubMed ID: 16712929
[TBL] [Abstract][Full Text] [Related]
17. Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization.
Shen YQ; Hebert G; Lin LY; Luo YL; Moze E; Li KS; Neveu PJ
J Neuroimmunol; 2005 Jan; 158(1-2):14-25. PubMed ID: 15589033
[TBL] [Abstract][Full Text] [Related]
18. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice.
Rojo AI; Montero C; Salazar M; Close RM; Fernández-Ruiz J; Sánchez-González MA; de Sagarra MR; Jackson-Lewis V; Cavada C; Cuadrado A
Eur J Neurosci; 2006 Oct; 24(7):1874-84. PubMed ID: 17067291
[TBL] [Abstract][Full Text] [Related]
19. MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact.
Lau YS; Novikova L; Roels C
Neurosci Res; 2005 Aug; 52(4):371-8. PubMed ID: 15936837
[TBL] [Abstract][Full Text] [Related]
20. Taurine fails to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion in mice.
Navneet AK; Appukuttan TA; Pandey M; Mohanakumar KP
Amino Acids; 2008 Aug; 35(2):457-61. PubMed ID: 17701098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]